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Sexualized intravenous drug use, also known as slamsex, seems to be increasing among
HIV-positive men who have sex with men (MSM). Physical and psychopathological symp-
toms have previously been reported in this population, although research on the subject of
slamsex is scarce. The objectives of our study were to describe the psychopathological
background of a sample of HIV-positive MSM who engaged in slamsex during the previous
year and to compare physical, psychopathological, and drug-related symptoms between
these participants and those who engaged in non-injecting sexualized drug use.
Design and methods
Participants (HIV-positive MSM) were recruited from the U-Sex study in 22 HIV clinics in
Madrid during 2016–17. All participants completed an anonymous cross-sectional online
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survey on sexual behavior and recreational drug use. When participants met the inclusion
criteria, physicians offered them the opportunity to participate and gave them a card with a
unique code and a link to access the online survey. The present analysis is based on HIV-
positive MSM who had engaged in slamsex and non-injecting sexualized drug use.
Results
The survey sample comprised 742 participants. Of all the participants who completed the
survey, 216 (29.1%) had engaged in chemsex, and of these, 34 (15.7%) had engaged in
slamsex. Participants who engaged in slamsex were more likely to have current psychopa-
thology (depression, anxiety, and drug-related disorders) than participants who engaged in
non-injecting sexualized drug use. In addition, participants who engaged in slamsex more
frequently reported high-risk sexual behaviors and polydrug use and were more often diag-
nosed with sexually transmitted infections (STIs) and hepatitis C than those who did not
inject drugs. Compared with participants who did not inject drugs, participants who engaged
in slamsex experienced more severe drug-related symptoms (withdrawal and dependence),
symptoms of severe intoxication (loss of consciousness), and severe psychopathological
symptoms during or after slamsex (eg, paranoid thoughts and suicidal behaviors).
Conclusion
Slamsex is closely associated with current psychiatric disorders and severe drug-related
and psychiatric symptoms.
Introduction
Chemsex, or sexualized drug use, was first described in the UK as the intentional use of recrea-
tional drugs to enhance sexual relations between men who have sex with men (MSM), usually
for long periods of time and often with multiple partners [1]. The main drugs involved in this
practice are mephedrone, γ-hydroxybutyrate/γ-butyrolactone (GHB/GBL), and crystal-meth-
amphetamine (crystal-meth) [2], although other drugs have also been reported, including keta-
mine, other synthetic cathinones, 3,4-methylenedioxymethamphetamine (MDMA), cocaine,
poppers, and erectile-dysfunction drugs, [3]. Other aspects of this phenomenon, such as the
use of geosocial networking applications to locate or participate in sex parties, should be taken
into consideration because of their relevance and implications [4]. The use of smartphone
applications (apps) designed to enable MSM to find casual sexual partners has been linked to a
higher number of sexual partners, a higher probability of engaging in unprotected anal inter-
course, and a higher probability of having been diagnosed with a sexually transmitted infection
(STI) [5].
Intravenous use of psychoactive substances in this context, especially stimulants such as
mephedrone and crystal-meth, is known as slamming or slamsex [2]. Some studies have sug-
gested that the practice of injecting recreational drugs at sex parties might be increasing
among MSM. For instance, Glass et al. [6] reported that since 2000, the proportion of MSM
who inject drugs has increased (from 4.4% in 2000/01 to 8.4% in 2014/15, P<0.001) among
users of general drug services in England. Both slamsex and non-injecting sexualized drug use
are more prevalent in MSM living with human immunodeficiency virus infection (HIV-posi-
tive) than HIV-negative MSM [7].
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Slamsex has been associated with group sex, condomless sex with casual partners, and fist-
ing, all of which increase the frequency of STIs and the transmission of viral infections, such as
those caused by HIV and hepatitis C virus (HCV) [7].
Both mephedrone and crystal-meth are potent central nervous system stimulants that also
act peripherally. The potency and half-life of mephedrone depends on the route of administra-
tion. If administered orally, onset of action takes half an hour, with a mild high that can last
from 3 to 5 hours. Intranasal administration leads to a potent high after 15 minutes that lasts
1–2 hours. With intravenous administration, the high is almost immediate and very potent
and lasts 30 to 45 minutes. The rapid onset of action and fast dissipation of effects leads to a
compulsive pattern of use and the need to re-dose almost every hour. Thus, high doses of
mephedrone are used in sexual settings, with the consequent risk of overdosing, altered behav-
ior, and delusional thoughts.
Crystal-meth differs from mephedrone in that its potency is similar irrespective of whether
it is injected intravenously or smoked. Either route of administration produces immediate
onset of action, within 0 to 2 minutes, and leads to a very potent high. If it is injected intrave-
nously, the effect can last almost 8 hours. Crystal-meth produces an intense state of excite-
ment, with euphoria and increased self-confidence and sociability. Given that its withdrawal
syndrome is very unpleasant, its addictive potential is very high [8].
Both substances have been related to induced psychotic symptoms in diverse populations
[9,10]. However, the appearance of psychiatric symptoms associated with slamsex is scarce,
although there is evidence suggesting that mephedrone used in slamsex can induce psychotic
symptoms and suicidal behavior [11]. Crystal-meth has also been related to high levels of
addiction, psychotic symptoms, and other psychiatric disorders in the context of chemsex
[12].
Mental health issues have been poorly studied among persons who engage in chemsex, and
few data are available on the severity of drug-related symptoms in HIV-positive MSM who
engage in slamsex.
The aim of our study was to compare the physical and psychopathological background (his-
tory of STIs, sexual behaviors, and diagnosed mental disorders such as depression and anxiety)
of HIV-positive MSM who engaged in slamsex with that of those who engaged in non-inject-
ing sexualized drug use. We also explored the presence of psychopathological symptoms and
symptoms of substance use disorders during or after drug use in the study population and
investigated associated factors. Patients were selected from the U-SEX GESIDA study [13].
Materials and methods
The present analysis is nested in the U-SEX GESIDA 9416 study, which was conducted in 22
HIV clinics in the Madrid area from June 2016 to March 2017. The study aimed to calculate
the prevalence of chemsex and associated factors in a sample of HIV-positive MSM in Spain.
The inclusion criteria were age�18 years, documented HIV infection, and being an MSM
(homosexual or bisexual). Infectious diseases physicians offered all the participants who met
the inclusion criteria the opportunity to participate and gave them a card with a unique ID
code and a link that enabled access to an online survey. Cards were non-transferable. The
unique ID code was given to each participant to allow them access to the website and complete
the survey. The ID code prevented people not selected for the study from responding to the
survey and was not linked to the participant’s identifying data. The physician evaluated the
rate of response and the representativeness of the sample (code, age, year of HIV diagnosis,
level of education, and nationality). The survey was self-completed outside the hospital to
ensure anonymity and confidentiality.
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The online survey was designed ad hoc by the research team to evaluate various domains:
general sociodemographic data (age, occupational status, income), HIV infection status (year
of diagnosis, treatment, adherence), sexual behaviors (condom use, receptive anal sex, fisting),
diagnosis of STIs (including HCV), diagnosed psychiatric disorders, and history of drug use. If
the participant reported any kind of drug use, he was asked if these drugs were used before or
during sexual encounters. Chemsex was defined as the intentional use of mephedrone or other
cathinones, MDMA, methamphetamine, GHB/GBL, ketamine, or cocaine during sex. This
analysis included participants who reported having engaged in chemsex in the previous 12
months. The survey evaluated the type of drugs used, the context in which they were used, fre-
quency of use, route of administration, and other aspects related to chemsex (eg, setting).
In order to collect data on psychiatric disorders, the survey asked general questions regard-
ing previously diagnosed psychiatric disorders and specific questions about “past” or “current”
psychiatric disorders diagnosed by a mental health specialist. We only considered self-reported
current psychiatric disorders (diagnosed in the previous year), namely, depression, anxiety,
personality disorders, psychosis, and drug-related disorders. Because the survey was self-com-
pleted, we used the term “self-reported current psychiatric disorder”.
All participants were asked about dependence, withdrawal, and psychopathological symp-
toms related to the drugs used during chemsex. To determine symptoms of drug dependence,
the survey asked about the following items: drugs used more often or in a higher quantity than
planned, severe craving, not fulfilling obligations because of drug use, continuing drug use
(even when this leads to physical or psychological discomfort), need to increase doses to obtain
the same effect, and less positive effects with the same doses. For purposes of the analysis,
dependence was defined as the presence of three or more symptoms of drug dependence dur-
ing the previous year.
In order to collect data on withdrawal symptoms we asked about the following: severe crav-
ing, need to take medications/other drugs to compensate for discomfort, sleep disturbances
(insomnia, hypersomnia), agitation, depressive thoughts/feelings, paranoid ideation, suicidal
thoughts, suicide attempts, and the need to see a doctor for treatment of discomfort. The pres-
ence of three or more withdrawal symptoms during the previous year was also recorded.
Finally, intoxication-related symptoms were assessed based on the following: sleep distur-
bances, “things done to me that I would not have consented to without being on drugs”, “more
sexual risk practices that I don’t do when not on drugs”, unpleasant physical feelings under the
effects of drugs, anxiety/panic attacks, irritability, and aggressiveness. Psychotic symptoms
(mainly paranoid ideation), loss of consciousness, suicidal thoughts, and suicide attempts were
considered to be symptoms of severe intoxication.
Details of the study procedures have been published elsewhere [13]. In order to clarify ter-
minology, participants were considered to have engaged in slamsex when they engaged in sex-
ualized intravenous drug use and in non-injecting sexualized drug use when the drugs were
not consumed intravenously.
The study protocol was approved by the Ethics Committee of Hospital Universitario Gre-
gorio Marañón (HUIL 1606 96/16) and fulfilled the principles of the Declaration of Helsinki
(2008).
Study data were collected and managed using the data capture tool Research Electronic
Data Capture (REDCap) [14], which is hosted at “Asociación Ideas for Health”.
Statistical analysis
Categorical variables were expressed as absolute and relative frequencies; continuous variables
were expressed as median (IQR). Baseline characteristics were compared between participants
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who had engaged in slamsex and participants who had engaged in non-injecting sexualized
drug use during the previous year using the chi-square test for categorical variables and the t
test for continuous variables. Variables included in the comparisons were sociodemographic
variables, self-reported current psychiatric disorders, physical and severe psychopathological
symptoms related to drug use/abuse, sexual behaviors, and medical variables such as time
since HIV diagnosis, self-reported adherence to antiretroviral therapy, and diagnosis of an
STI.
We conducted a logistic regression analysis to explore the association between slamsex and
symptoms of drug use disorders/severe psychopathological symptoms. We performed separate
tests to examine the association between slamsex and the following: presence of withdrawal
symptoms (three or more withdrawal symptoms), dependence (three or more dependence-
related symptoms), craving (increased need for consumption), paranoid ideation (during or
after drug use), suicidal behaviors (suicidal ideation and suicide attempts during or after drug
use), and loss of consciousness (during or after drug use).
The univariate analysis was conducted separately to evaluate the association between symp-
toms of drug-related disorders or severe psychopathological symptoms in the context of chem-
sex and other drug-related variables or self-reported current psychiatric disorders. The
dependent variables included withdrawal symptoms, severe craving, psychotic paranoid idea-
tion, suicidal behaviors, and loss of consciousness. Independent variables were categorized as
the presence/absence of self-reported active depression, self-reported active anxiety, polydrug
use (three or more drugs used during a session), cathinone use during the previous year, keta-
mine use during the previous year, GHB use during the previous year, and smoking crystal-
meth during the previous year. Thereafter, bivariate logistic regression analysis was conducted
to explore associations regardless of the presence of slamsex. The presence/absence of slamsex
was included in the bivariate regression as an independent variable. Independent variables
were included in the bivariate analysis only if their p value was�.10 in the univariate analysis.
Results
1.1. Baseline characteristics and comparison between participants who
engaged in slamsex and participants who engaged in non-injecting
sexualized drug use
Of a total of 742 HIV-positive MSM who completed valid surveys in the U-Sex Study, the pres-
ent analysis included all the participants who had engaged in chemsex during the previous
year (N = 216). Participants in our sample were mainly Spanish-born (71.3%), middle aged
(median = 38; IQR: 33–44), and educated to university level (63.9%). In addition, 70.8% had a
salary of more than 1000 euros per month, and 42% were in a stable relationship. The median
time with HIV diagnosis was five years (IQR: 2–11). More than 90% were receiving antiretro-
viral therapy, and of these, 3% reported having taken less than 90% of their doses (poor adher-
ence). In our sample, 34 participants (15.7%) had engaged in slamsex during the previous year.
A comparison with HIV-positive MSM who did not engage in chemsex in our sample has
been reported elsewhere [13].
When participants who had engaged in slamsex during the previous year were compared
with those who engaged in non-injecting sexualized drug use, no differences were found
regarding sociodemographic or medical variables. Compared with people who engaged in
non-injecting sexualized drug use, people who had engaged in slamsex were less likely to have
a stable partner (26.5 vs. 45.6%, P = .039) and were more likely to have suboptimal adherence
to antiretroviral therapy (9.1 vs. 1.9%, P = .061).
Slamsex and psychopathological symptoms
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Comparisons based on the type of drug used in both groups of participants are shown in
Table 1.
Participants who engaged in slamsex had higher rates of polydrug use (three or more drugs
per session) and more frequently used mephedrone and other cathinones, crystal-meth, and
ketamine. They were also more likely to administer the drugs rectally and had higher rates of
high-risk drug use behaviors, such as sharing needles and other drug paraphernalia. Symptoms
related to drug abuse/dependence and severe psychopathological symptoms associated with
the practice of slamsex and non-injecting sexualized drug use are shown in Table 2.
The drugs most frequently injected intravenously were mephedrone and other cathinones
(94.1%), followed by ketamine (17.6%), crystal-meth (5.9%), and cocaine (5.9%).
Participants who engaged in slamsex had a significantly higher percentage of sexual risk
behaviors than those who engaged in non-injecting sexualized drug use, as follows: fisting
(73.5 vs. 38.5%, P = .001), fisting without a glove (67.7 vs. 28%, P = .001), condomless sexual
relations (93.1 vs. 48.3%, P = .001), and more than 20 sexual partners in the previous 6 months
(70 vs. 39.6%, P = .002). As for STIs, people who had engaged in slamsex more often had gon-
orrhea (61.8 vs. 43.4%, P = .049), syphilis (88.2vs. 62.6%, P = .004), and hepatitis C (61.8% vs.
18.1%, P = .000) than people who engaged in non-injecting sexualized drug use.
A self-reported current psychiatric disorder was more common among participants who
engaged in slamsex than in those who engaged in non-injecting sexualized drug use. The con-
ditions reported were as follows: depressive disorder (61.8 vs. 28%, P = .0001), anxiety disorder
Table 1. Comparisons between participants who engaged in non-injecting sexualized drug use and participants who engaged in slamsex in terms of type of drug
used in the previous year.
Total sample (N = 216) Non-injecting sexualized drug use
(n = 182)
Slamsex (n = 34) P value
Polydrug, No. (%) 98 (45.4) 70 (38.5) 28 (82.4) .000
Poppers, No. (%) 170 (78.7) 140 (76.9) 30 (88.2) .139
Mephedrone or other cathinones, No. (%) 150 (69.4) 116 (63.7) 34 (100) .000
Cocaine, No. (%) 171 (79.1) 146 (80.2) 25 (73.5) .378
MDMA, No. (%) 105 (48.6) 87 (47.8) 18 (52.9) .582
GHB, No. (%) 155 (71.7) 128 (70.3) 27 (79.4) .280
Crystal-methamphetamine,
No. (%)
64 (29.6) 47 (25.8) 17 (50) .005
Ketamine, No. (%) 78 (36.1) 57 (31.3) 21 (61.8) .001
Rectal use of drugs, No. (%) 44 (20.4) 24 (13.2) 20 (58.8) .000
High-risk drug use, No. (%) 168 (77.8) 135 (74.2) 33 (97.1) .003
https://doi.org/10.1371/journal.pone.0220272.t001
Table 2. Self-reported psychiatric symptoms during and after non-injecting sexualized drug use and slamsex.
Total sample (N = 216) Non-injecting sexualized drug use
(n = 182)
Slamsex (n = 34) P value
3 or more dependence symptoms, No. (%) 60 (27.8) 40 (22) 20 (58.8) .000
3 or more withdrawal symptoms, No. (%) 98 (45.8) 72 (39.6) 26 (76.5) .000
Intense craving, No. (%) 55 (25.5) 34 (18.5) 21 (61.8) .000
Interference with work, social, or family life, No. (%) 68 (31.5) 46 (25.3) 22 (64.7) .000
Paranoid ideation, No. (%) 30 (15.3) 20 (11) 10 (29.4) .004
Suicidal ideation, No. (%) 33 (15.3) 22 (12.1) 11 (32.4) .003
Suicide attempt, No. (%) 30 (13.8) 19 (10.4) 11 (32.4) .001
Loss of consciousness, No. (%) 33 (15.3) 23 (12.6) 10 (29.4) .013
https://doi.org/10.1371/journal.pone.0220272.t002
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(47.1 vs. 23.1%, P = .004), and drug use disorders (drug-dependence) (38.2 vs. 15.4%, P =
.002).
1.2. Correlates of severe physical and psychopathological symptoms related
to drug use
The simple logistic regression conducted to explore the association between slamsex and the
presence of symptoms of drug use disorders or severe psychopathological symptoms related to
drug use revealed a significant association. Compared with participants who had engaged in
non-injecting sexualized drug use, those who engaged in slamsex were five times more likely
to have experienced withdrawal symptoms (OR: 4.97 [2.13–11.57], P = .0001) and seven times
more likely to have experienced intense craving (OR: 7.03 [3.21–15.43], P = .0001). Moreover,
during or after drug use they were three times more likely to experience suicidal ideation (OR:
3.48 [1.48–8.10], P = .004), psychotic paranoid ideation (OR: 3.38 [1.41–8.07], P = .006), and
loss of consciousness (OR: 2.88 [1.22–6.79], P = .016).
Figs 1–4 show the associations between other drug-related variables/current self-reported
psychiatric diagnosis and the presence of symptoms of drug-related disorders and severe phys-
ical and psychopathological symptoms related to drug use (suicidal ideation, paranoid idea-
tion, 3 or more withdrawal symptoms, and 3 or more drug-dependence symptoms), regardless
of the presence of slamsex.
Participants who self-reported current depressive disorders more frequently had with-
drawal symptoms. Active anxiety, cathinone use, and GHB use were also associated with the
presence of withdrawal symptoms. Moreover, participants who smoked crystal-meth more fre-
quently experienced severe craving, and those who smoked crystal-meth or used multiple
Fig 1. Association between current self-reported psychiatric diagnosis and 3 or more withdrawal symptoms.
https://doi.org/10.1371/journal.pone.0220272.g001
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Fig 2. Association between current self-reported psychiatric diagnosis and 3 or more drug-dependence symptoms.
https://doi.org/10.1371/journal.pone.0220272.g002
Fig 3. Association between current self-reported psychiatric diagnosis and psychotic symptoms.
https://doi.org/10.1371/journal.pone.0220272.g003
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drugs were significantly more likely to present symptoms of drug dependence. Suicidal idea-
tion was only associated with self-reported depression and anxiety disorders; paranoid idea-
tion was associated with anxiety disorders, polydrug use, and smoked crystal-meth. Finally,
loss of consciousness was related to polydrug use, GHB use, ketamine use, and smoked crystal-
meth.
Discussion
The present study provides novel findings regarding the slamsex phenomenon in a sample of
HIV-infected MSM who engage in sexualized drug use. In our sample, 216 subjects engaged in
chemsex. From this sub-sample, 34 subjects (15.7%) had engaged in slamsex during the previ-
ous year. Compared with those who did not inject drugs, people who had engaged in slamsex
more frequently reported high-risk sexual behaviors, had more frequently been diagnosed
with an STI, and had more frequently reported a current diagnosis of a psychiatric disorder. In
addition, compared with participants who engaged in non-injecting sexualized drug use, par-
ticipants who had engaged in slamsex in the previous year had more drug-related adverse
effects such as symptoms of withdrawal and dependence or severe physical and psychopatho-
logical symptoms, such as psychotic paranoid ideation, suicidal behaviors, and loss of con-
sciousness. Based on the route of consumption, we compared these two sub-groups to evaluate
potential differences between people who used the same drugs in a sexual context and to ana-
lyze whether there were differences regarding psychopathological background. We also deter-
mined whether the group who injected drugs had more drug-related symptoms, as might be
expected. Because of the design of the survey and the fact that psychiatric conditions were self-
reported, we cannot suggest causality and can only report whether there were differences
Fig 4. Association between current self-reported psychiatric diagnosis and suicidal ideation or attempt.
https://doi.org/10.1371/journal.pone.0220272.g004
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between the groups and whether psychiatric background correlated with drug-related symp-
toms. This limitation raises the need for structured studies among MSM who attend HIV clin-
ics. Such studies should be performed by trained mental health professionals operating within
multidisciplinary programs who can assess mental health through personal interviews and
structured scales. In this way, we would be able to diagnose and treat possible mental disorders
in this population. The assessment of drug-related disorders can be addressed in the same
manner, thus making it possible to detect drug-related problems early, apply harm-reduction
approaches, and prevent potential problems related to sexualized drug use.
Data have been published on the prevalence of slamsex and associated high-risk behaviors
among MSM. The Unlinked and Anonymous Monitoring (UAM) survey of people who inject
drugs conducted in general drug services across England, Wales, and Northern Ireland
reported a significant increase in the proportion of MSM who inject drugs from the year 2000
to 2015. They also reported the presence of high-risk behaviors associated with injecting such
as needle/syringe sharing (15% vs. 11%, P = 0.07) and having more than 10 sexual partners
among MSM who injected drugs than among MSM who did not inject drugs (25% vs. 4.0%,
P<0.001) [6]. A recent study from an Australian cohort of MSM reported a high life preva-
lence of injecting drugs (10.3%); the prevalence of injection in the previous six months was
4.7% in this population. The authors reported that injecting drugs was associated with high-
risk sexual practices such as having multiple sex partners, group sex with casual partners, and
condomless anal intercourse with casual partners [15]. In the case of HIV-positive MSM, the
ASTRA study [16] reported that of 2248 HIV-positive sexually active MSM recruited in 2011–
2012, 1138 (51%) had used recreational drugs in the previous three months and that the preva-
lence of injection drug use was 3% (n = 68). The Positive Voices study reported that 105 of 392
sexually active HIV-positive MSM (29%) had engaged in chemsex during the previous year.
Among these, the prevalence of slamsex was 33.3% [17]. The prevalence of slamsex in our
study could be directly compared with the findings of the Positive Voices study only because
of methodological and sample-related similarities. While the frequency of chemsex reported is
similar to that we reported (29%) in the U-Sex Study [13], the authors found higher frequen-
cies of slamsex among their participants (33.3 vs. 15.6%). Therefore, we think that regional dif-
ferences in slamsex frequencies should be explored in future studies. The most dangerous
profiles of drug use and sexual practices found in the abovementioned studies in samples of
MSM who injected drugs are congruent with the higher frequencies of polydrug use, rectal
administration, sharing drug paraphernalia, sexual risk behaviors, and STIs found among
those who engaged in slamsex in the present study.
We found that the most common intravenous drugs used during slamsex were mephedrone
and other synthetic cathinones (94.1%), followed by ketamine (17.6%), crystal-meth (5.9%),
and cocaine (5.9%). To our knowledge, only a few reports discuss the type of drug used by
HIV-positive MSM during slamsex. The UAM Survey found high frequencies of injected
mephedrone and ketamine among MSM who injected drugs (12% and 9.3%, respectively) [6].
Furthermore, data from Antidote, a specialist drug clinic aimed at the gay community in Lon-
don, UK showed that 75% of patients used mephedrone in chemsex and that of these, 80%
injected the drug. Of this 80%, 75% were HIV-positive and 70% reported sharing needles [18].
The recently published FLUX study, a survey performed in Australian gay and bisexual men,
found that of the 1995 respondents, 206 (10.3%) reported having injected drugs and 93 (4.7%)
had injected recently, most commonly crystal-meth (91.4%) and speed (9.7%), as well as
cocaine and ketamine, albeit in low percentages [15]. Together with the data reported above,
our results suggest that the type of drugs injected in slamsex are similar, but that there may be
regional differences. Drug use in the context of slamsex and non-injecting sexualized drug use
Slamsex and psychopathological symptoms
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may be changing as a result of travel by MSM to different countries for leisure, socialization,
and clubbing and to expand sexual experiences.
The participants in our sample who engaged in slamsex presented a higher frequency of
drug-related adverse effects than those who engaged in non-injecting sexualized drug use.
Severe craving and other withdrawal symptoms were more frequent, as was loss of conscious-
ness. The participants also had higher rates of severe psychopathological symptoms such as
paranoid ideation and suicidal ideation or attempts.
Mephedrone and other synthetic cathinones were the main drugs “slammed” in our sam-
ple, both as stimulants and as sexual enhancers. The intravenous injection of mephedrone has
been related to compulsive use, intense craving, binging behaviors, and withdrawal symptoms
[19]. Diverse psychotic symptoms, mainly paranoid ideation, have also been reported for
mephedrone, especially if it is consumed intravenously [20,21]. In the context of slamming,
one case in Spain was reported in a young HIV-positive man who experienced persistent
mephedrone-induced paranoid delusions, intense anxiety, and visual and kinesthetic halluci-
nations [11].
Ketamine, cocaine, and crystal-meth were also consumed in slamsex in our sample, albeit
at a lower frequency than cathinones. Injected crystal-meth has the potential to induce psy-
chotic symptoms and has been associated with drug-related disorders such as abuse or depen-
dence. In slamsex, its potent stimulant effect has been related to high-risk sexual behaviors,
with an increased risk of HIV infection and other STIs [8].
Traditionally, more frequent drug dependence and psychiatric symptoms have been
described during intoxication by or abstinence from some drugs if they are used intravenously.
Our novel data, together with the few previously published findings, support the addictive
potential and severe psychopathological symptoms associated with sexualized intravenous
drug use.
Other variables related to drug use might modulate the severity of physical and psychopath-
ological symptoms in the context of non-injecting sexualized drug use. In our sample of HIV-
infected MSM who engaged in non-injecting sexualized drug use, regardless of the presence of
slamsex, the factors associated with more severe physical and psychopathological drug-related
symptoms were smoked crystal-meth, GHB use (oral), ketamine, polydrug use, and self-
reported depression and anxiety disorders. In particular, smoked crystal-meth was associated
with higher rates of drug dependence and withdrawal symptoms. Moreover, participants who
smoked crystal-meth more frequently had psychotic paranoid ideation and experienced loss of
consciousness during or after drug use.
In addition to being injected intravenously, crystal-meth has been smoked by MSM at sex
parties during the last decade, mainly in the London gay scene [22]. The potent disinhibiting
effect of this drug has been related to high-risk sexual behaviors and an increase in the fre-
quency of STIs, particularly HIV infection [23]. Furthermore, drug dependence has been
described in MSM who inject crystal-meth and who are also more prone to comorbid psychi-
atric disorders and suicidal behavior [23]. Psychotic symptoms have been reported in other
populations [24], although additional psychopathological symptoms induced by smoked crys-
tal-meth in chemsex are uncommon.
Loss of consciousness was also associated with GHB and ketamine use in our sample. In
addition, participants who used more than three drugs (polydrug use) had higher rates of loss
of consciousness and paranoid ideation and tended to experience more pronounced symp-
toms of drug dependence. This observation must be taken into account, because GHB is usu-
ally consumed in combination with other drugs. GHB is frequently related to loss of
consciousness, owing to its depressive effect on the central nervous system and the fact that it
accumulates over time [2]. In addition, the combination of GHB with mephedrone, crystal-
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meth, and alcohol increases the risk of drug-drug interactions and overdose, with loss of con-
sciousness and respiratory depression [2]. Although ketamine is a dissociative anesthetic that
acts as a stimulant at low doses, with higher doses, polydrug use, and intravenous injection, it
can increase the risk of loss of consciousness and cardiovascular toxicity in recreational set-
tings [25] such as chemsex, as reported in the present study. Our results are congruent with
the previously known effects of these drugs (crystal-meth, GHB, mephedrone). The results of
the present study can help us to understand the role of each type of drug and of the route of
administration in the severe psychopathological symptoms that may be experienced by people
who engage in non-injecting sexualized drug use.
Finally, self-reported current diagnosed psychiatric disorders may have played a significant
role among the participants who engaged in slamsex and in non-injecting sexualized drug use
in our sample. Regardless of the presence of slamsex, those participants who self-reported cur-
rent depression more frequently experienced withdrawal symptoms and suicidal ideation dur-
ing or after drug use. Participants with current anxiety disorders also reported higher
frequencies of withdrawal symptoms, suicidal ideation, and paranoid ideation in this context.
Moreover, participants who engaged in slamsex were more likely to have been diagnosed with
an anxiety disorder or a depressive disorder.
While there is evidence that HIV-positive MSM frequently present mental disorders such
as depression, anxiety, and suicidal behavior, as well as drug-related disorders, there is little
research on the effect of these variables on the health consequences of chemsex in this popula-
tion. The initial published data suggest that HIV-positive MSM who engage in chemsex had a
higher frequency of depression and anxiety disorders than HIV-positive MSM who did not
[26]. Other studies on chemsex did not report psychopathological diagnoses, but rather ana-
lyzed the emotional distress and psychological discomfort associated with chemsex. It has been
suggested that the vulnerability factors related to problematic use of drugs in chemsex may
include the so-called minority stressors, such as negative internalized homophobia, fear of dis-
approval, experience of discrimination, and a negative self-concept [27].
Therefore, according to the syndemic approach, mental health disorders in HIV-infected
MSM appear to increase vulnerability to drug abuse disorders and sexual risk behaviors in a
framework by which disease outcomes and the social conditions that contribute to their
proliferation sustain each other [27]. Consequently, a multidisciplinary approach is neces-
sary to address the situation appropriately. Although the design of the present study and its
limitations do not allow us to establish causality, in our opinion, the presence of depression
and anxiety among HIV-positive MSM who engage in slamsex could act as a vulnerability
factor that modulates the severity of physical and psychopathological symptoms during or
after intravenous sexualized drug use. Moreover, people with previous mental health disor-
ders may be more likely to start chemsex and become involved in high-risk practices such as
slamsex for various reasons, such as low self-esteem, the need to be accepted by a group,
self-neglect, and the desire to avoid negative feelings. These issues may be considered syn-
demic factors and should be further addressed in studies that delve deeper into mental
health problems and enable us to evaluate possible mental disorders and their relationship
with drug-use disorders [27]. Although we found that suicidal behaviors in participants
who engaged in slamsex were associated with current depression and anxiety, they were
also present in participants who reported anxiety and depression and engaged in non-
injecting sexualized drug use. These findings suggest that people with depression or anxiety
who engage in sexualized drug use are more vulnerable to developing suicidal behavior. In
addition, intravenous use of specific drugs such as synthetic cathinones and other stimu-
lants can trigger suicidal ideation in vulnerable individuals, mainly those who have already
been diagnosed with depression or anxiety. Furthermore, as mentioned earlier, persons
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with current depression or anxiety may be more likely to use drugs intravenously, as they
are less concerned about their personal welfare and the potential risk behaviors related to
drug use. These associations suggest that the combination of psychopathology and intrave-
nous drug use may facilitate suicidal ideation, suicide attempts, and psychotic symptoms in
affected persons. However, while people with psychiatric disorders may be more vulnerable
to suicidal ideation, intravenous consumption of drugs (such as mephedrone) and smoked
crystal-meth can induce psychiatric symptoms as a result of their own effects. More research
is needed to determine the relationship between these variables in people who engage in
slamsex and non-injecting sexualized drug use.
We think it is important to evaluate the mental health of HIV-positive MSM alongside
other routine evaluations conducted in HIV clinics. The detection of psychiatric disorders and
their appropriate treatment can prevent potential mental and physical consequences of drug
use in this population. In addition, approaches such as reducing the harm caused by drug use
can be more effective in people who are not willing to stop sex-related drug use. It is necessary
to create multidisciplinary approaches aimed at preventing and treating the potential conse-
quences of slamsex and non-injecting sexualized drug use in this population.
To our knowledge, this is the first detailed analysis of drug-related and severe psychopatho-
logical symptoms in people who engage in slamsex. We also report data that increase our
knowledge of the role of different types of drugs, routes of consumption, and psychiatric back-
grounds, as well as drug-related symptoms and psychopathological symptoms associated with
slamsex and non-injecting sexualized drug use among HIV-positive MSM.
Our study is subject to the limitations inherent to cross-sectional survey-based studies,
especially response bias. Although we used limited time periods in questions that depended on
memory, recall bias could distort the accuracy of the results. Furthermore, we cannot suggest
causality because of the cross-sectional nature of the study. Longitudinal studies should be
performed to compare our results in order to be able to discuss whether slamsex is related to
previous psychopathology and contributes to the presence of drug-related and severe psycho-
pathological symptoms in HIV-positive MSM. Another limitation is that the psychiatric diag-
nosis and drug-related symptoms were self-reported. Although the questionnaire specified
previous or current psychiatric disorders diagnosed by a psychiatrist or other mental health
specialist, the survey did not have standardized diagnostic scales. The exploratory nature of
this study led to the inclusion of a large number of variables and the ad hoc design of the sur-
vey. In addition, the language used for questioning was not always standardized and had to be
adjusted for the individual patient, with frequent use of slang terms. However, questions about
substance dependence and withdrawal were elaborated following DSM-IV-Rev criteria. Future
studies should include standardized screening scales for mental disorders, substance use disor-
ders, presence of craving, and specific psychopathological symptoms to enable detailed mea-
surement of specific variables.
Our results suggest that slamsex is relatively common, although it does not appear to be
generalized among HIV-positive MSM who engage in chemsex in Spain. People who engage
in slamsex more frequently seem to have high-risk practices associated with both drug use and
sexual behaviors than people who engage in non-injecting sexualized drug use. Furthermore,
people who engage in slamsex are more likely to experience drug-related psychopathological
symptoms and symptoms of drug dependence. Moreover, the non-injected use of other sub-
stances, such as crystal-meth, GHB/GBL, and ketamine, and the presence of psychiatric disor-
ders might also be related to severe consequences for the physical and mental health of HIV-
positive MSM who engage in chemsex.
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